RNS out27 Apr 2020 14:44
Patients infected with COVID-19 are known to develop an uncontrolled immune response ("cytokine storm"), which results in excessive production of pro-inflammatory cytokines such as IL-6 and TNF- a both of which are regarded as key drivers of chronic inflammation and are believed to be associated with severe lung damage commonly observed in patients with COVID-19 infections and acute respiratory distress syndrome (ARDS). Therefore, Tiziana believes it is possible to potentially combine TZLS-501 (anti-IL6R) with NP-Act D to inhibit viral proliferation and to suppress inflammation in lungs to halt progression of COVID-19-mediated lung damage and death.